SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's stock is trending as investors discuss its potential inclusion in the S&P 500, with the official announcement expected soon. The community is weighing the potential for a short squeeze against the historical trend of stocks dropping after being added to the index. Optimistic traders believe the inclusion, along with upcoming events, will drive the stock higher.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as it joins the S&P 500, sparking excitement and debate about potential short squeezes and future price movement. The community is discussing whether the stock was pumped prior to the announcement and speculating on profit-taking strategies. Some investors express frustration for selling earlier, while others are optimistic about long-term growth.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to its low float, with traders speculating it could be the next stock to experience a significant squeeze. The community is actively discussing its potential for a rapid price increase, drawing comparisons to other low-float stocks that have recently made substantial moves. A recent land sale boosting NAV is also circulating.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is trending as traders discuss the implications of its new ticker symbol and potential connections to blockchain technology through Tzero, drawing comparisons to past meme stock surges like $GME. The community is actively debating whether this is a fresh start or another fleeting rally, and speculating about possible involvement from figures like Ryan Cohen. Some investors believe Overstock's transition to Bed Bath & Beyond, combined with blockchain assets, could drive a significant turnaround.

Pineapple Financial, Inc. is a Canadian based mortgage technology and brokerage company, which engages in the mortgage brokerage services and technology solutions to Canadian mortgage agents, brokers, sub-brokers, brokerages, and consumers. The company also provides back-office services, together with pre-underwriting support services. The company was founded by Shubha Dasgupta, Kendall Marin, and Charles Andrew Green on October 16, 2015 and is headquartered in North York, Canada.

Pineapple Financial Inc

Pineapple Financial ($PAPL) is trending due to a recently closed $100M private placement and a move into Injective (INJ) tokens, sparking high volatility. The community is buzzing about potential short squeezes and halts, with bulls anticipating further upside and bears cautioning about dilution. Traders are closely watching price action and momentum, with some eyeing new entries while others secure profits.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue ($KVUE) is trending due to discussions surrounding a report linking Tylenol use during pregnancy to autism, sparking community debate about the validity and potential market impact. Some investors view the dip as a buying opportunity, dismissing the report, while others express concern over potential lawsuits and long-term effects on the company. The broader context includes Kenvue's position as a consumer health company and its relationship with Johnson & Johnson.

K9 Finance, a Shibarium-based LSD platform, offers core DeFi services and acts as an official validator. Rewarding $KNINE holders with $BONE for block validation, it aims to drive DeFi adoption via the 'Roundtable of Dogs' DAO, which governs treasury and roadmap decisions.

K9 Finance DAO

K9 Finance DAO ($KNINE.X) is trending as the project continues to build on Shibarium, with the community actively discussing staking $BONE for $knBONE and earning rewards through yield farming. The launch of Bonecrusher v3 and the ongoing retro airdrop are also key catalysts driving interest in the project. K9 Finance aims to enhance DeFi within the Shiba Inu ecosystem, focusing on liquid staking and DAO governance.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG.X) is trending as the community rallies around the token's $SOL.X reward system for holders, emphasizing its potential for passive income. Despite some volatility and past challenges, the community highlights its resilience and the arrival of new developers, sparking renewed optimism. Discussions also focus on upcoming events and partnerships, contributing to the token's visibility.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

aTyr Pharma is trending as investors discuss the potential implications of recent inducement grants and upcoming Phase 3 data, with some speculating about the company's confidence in positive results based on hiring activity. Community perspectives are divided, with bullish arguments emphasizing the potential for a successful outcome and high price targets, while bearish viewpoints focus on past trial data and concerns about short selling strategies. The stock's high short interest and upcoming data readout are contributing to increased volatility and active conversation.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is trending as investors discuss its potential for recovery amid S&P 500 removal and debates around solar tax credits. Community talking points include the stock's downtrend, possible bottoming, and sensitivity to interest rate cuts, while some express concerns over policy and market conditions. Despite mixed sentiment, there's optimism about Enphase's technology and long-term prospects in the solar energy sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Therma Bright, Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX), a burgeoning name in the medical device industry, has achieved a significant breakthrough for its flagship product, the Venowave VW5. This circulation-enhancing device recently secured a crucial designation from the Centers for Medicare and Medicaid Services (CMS), positioning it for success within the expansive Medicare and Medicaid frameworks.The Venowave VW5 has been awarded a permanent Healthcare Common Procedure Coding System (HCPCS) code, a pivotal development that could propel Therma Bright into the forefront of the deep vein thrombosis (DVT) treatment market. Industry estimates project this market to grow to $1.5 billion by 2032, offering substantial growth prospects for Therma Bright, which currently holds a modest market cap of USD $21 million.Introducing Therma Bright: Innovating Blood Clot Prevention, and BeyondTherma Bright, Inc., the innovative force behind the Venowave VW5, specializes in cutting-edge diagnostic and medical device technologies. While the company boasts a diverse portfolio, the Venowave VW5 is currently generating the most investor enthusiasm.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_14_31_PM_5254def16f.png" alt="Screenshot 2024-09-10 at 5.14.31 PM.png">The Venowave VW5 is a device designed to be worn on the calf, where it generates wave-like motions to massage the leg and promote blood circulation. This function is critical in pushing blood back to the heart, helping to prevent blood clotting, particularly in cases of DVT—a condition that affects approximately 900,000 Americans annually, according to the CDC. Unlike traditional compression socks, which can cause discomfort and skin issues, the VW5 offers a more comfortable and effective alternative for DVT patients.Venowave VW5 Achieves Key Medicare &amp; Medicaid DesignationThe Venowave VW5 is the first device of its kind to be classified as Durable Medical Equipment (DME) with a new HCPCS Level II code. This designation enhances the device's credibility as a treatment option and streamlines billing and reimbursement processes through Medicare and Medicaid. This is expected to increase its appeal among patients seeking treatment for DVT.Medicare and Medicaid reimbursement is crucial for a company like Therma Bright because it opens the door to a vast and stable market of insured patients, ensuring consistent demand for their products. Securing reimbursement from these programs not only validates the effectiveness and necessity of their devices but also simplifies the purchasing process for patients and healthcare providers. For investors, this is a significant milestone as it enhances the company’s revenue potential and reduces financial risk, making Therma Bright a more attractive and reliable investment opportunity.As per the recent announcement, patients will have the option to purchase a pair of Venowave devices outright with a capped reimbursement of $1,199. Alternatively, they can opt for a rental plan, with monthly reimbursement capped at $78.05, totaling $819.55 over 13 months. Ownership of the device will transfer to the patient after the 13th rental payment.Strategic Distribution Partnership SecuredShortly after receiving its new designation, Therma Bright announced a partnership with a major distributor to launch an initial sales program. This initiative aims to assess Medicare and Medicaid reimbursement timelines and billing procedures. If successful, the distributor has agreed to purchase the remaining Venowave VW5 inventory, valued at $2.38 million.While the distributor's identity has not been disclosed, it is expected that further details will emerge as the program progresses. This partnership marks a crucial step towards establishing the VW5 as a preferred DVT treatment, particularly for patients covered by Medicare and Medicaid. Therma Bright's CEO, Rob Fia, anticipates a "significant increase" in monthly orders as a result.Beyond DVT: Expanding the Venowave VW5's ApplicationsWhile the Venowave VW5 is already gaining attention for its role in DVT treatment, its potential applications extend far beyond. The device is capable of addressing a wide range of conditions, significantly broadening Therma Bright's total addressable market.In addition to DVT, the VW5 can be used for:<ol><li>Managing symptoms of post-thrombotic syndrome (PTS)</li><li>Preventing primary thrombosis</li><li>Treating lymphedema</li><li>Reducing post-operative pain and swelling</li><li>Alleviating leg swelling caused by vascular insufficiency</li><li>Treating varicose veins</li><li>Managing chronic venous insufficiency</li><li>Enhancing blood circulation</li><li>Addressing intermittent claudication</li></ol>All of these ailments represent blue sky for Therma Bright as each one of these very common medical issues, as they potentially become approved, would unlock a whole new category of customer for the company.&nbsp;Therma Bright's Diverse, Late-Stage Product Pipeline&nbsp;Therma Bright's diverse product portfolio is a key driver of its investor appeal, with its investment in Inretio at the forefront.&nbsp;Inretio is revolutionizing ischemic stroke treatment with its Preva® clot-retrieval device, which has recently completed its<a href="https://finance.yahoo.com/news/therma-bright-major-milestone-portfolio-100000110.html"> third successful human trial</a>. This groundbreaking technology represents a significant leap in thrombectomy procedures, offering unmatched precision in restoring blood flow for stroke patients, even when traditional treatments like tPA fail.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_28_PM_5b99c7f619.png" alt="Screenshot 2024-09-10 at 5.15.28 PM.png">The Preva® device's patented protective basket design reduces the risk of embolization and minimizes the need for repeated maneuvers, positioning it as a potential game-changer in the global market for advanced clot removal solutions. As Inretio progresses towards FDA 510K designation, the success of the Preva® device underscores the strategic value of Therma Bright's investment in cutting-edge medical technologies.With the global coronary stents market expected to reach $4.8 billion by 2029, the continued development of this device could greatly enhance Therma Bright's portfolio.The $16 Billion COPD MarketTherma Bright is making significant strides with its investment in InStatin, a company developing innovative inhaled statin therapies for respiratory diseases like asthma and Chronic Obstructive Pulmonary Disease (COPD). Unlike traditional statin therapies that are administered orally, InStatin’s novel delivery system targets the airways and lungs directly, potentially offering a more effective treatment at lower dosages. This cutting-edge approach could revolutionize the management of these respiratory conditions, which collectively affect over 600 million people globally.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_34_PM_afe9034042.png" alt="Screenshot 2024-09-10 at 5.15.34 PM.png">The global market for asthma and COPD treatments is substantial, with an estimated value exceeding $16 billion annually. This presents a significant growth opportunity for Therma Bright as InStatin progresses through pre-clinical stages. The unique benefits of inhaled statins—such as reduced tissue thinning and longer-lasting therapeutic effects compared to steroids—position this technology as a promising alternative in a market that has seen little innovation over the past 50 years.With a 17% equity stake in InStatin and a 60% stake in Invixa, Therma Bright is well-positioned to capitalize on the success of these therapies.Turn Your Head and CoughTherma Bright has also played a pivotal role in developing the Digital Cough Test in collaboration with AI4LYF. This innovative app uses artificial intelligence to monitor various respiratory diseases through cough analysis, further diversifying Therma Bright’s product offerings.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_39_PM_68fe2a4028.png" alt="Screenshot 2024-09-10 at 5.15.39 PM.png">Bringing it all TogetherTherma Bright's strategic focus on both medical devices and drug therapies places the company in a unique position within the healthcare sector. The company’s flagship products—ranging from the Venowave VW5 for DVT prevention to the Preva® clot-retrieval device and inhaled statin therapies—target significant, multi-billion-dollar markets. Combined, the market opportunities across these indications surpass $22 billion globally, highlighting the substantial revenue potential for Therma Bright which pales in comparison to their tiny market value of just USD $21 Million.What sets Therma Bright apart is its emphasis on medical devices, which typically face shorter, less expensive, and less risky development timelines compared to pharmaceutical drugs. The company's advancements with the Venowave VW5 and Preva® device, both of which are already far along in the regulatory process, partially de-risk their pipeline. This progress contrasts with the longer, more expensive, and more uncertain path often associated with drug development.&nbsp;By focusing on innovative medical devices that address large and unmet medical needs, Therma Bright is poised to potentially capture significant market share, offering a compelling growth story for investors as it continues to push the boundaries of healthcare innovation.

Therma Bright (TBRIF) Stock Skyrockets After Medicare and Medicaid Milestone, Enters Multi-Billion-Dollar Market

Therma Bright’s Venowave VW5 achieves a Medicare code, boosting its market reach in DVT treatment. With new partnerships and a diverse product pipeline, the company is set for significant growth.

Therma Bright Gains Medicare Milestone, Expands into $1.5B Market

public companies

Therma Bright’s stock surges as its Venowave VW5 device secures a crucial Medicare and Medicaid designation, entering the $1.5B DVT market. With a strategic distribution partnership, Therma Bright is poised for rapid growth in medical devices and therapies.


Click to follow <a href="https://stocktwits.com/symbol/TBRIF">Therma Bright, Inc. </a>(TSXV: THRM) (<a href="https://stocktwits.com/symbol/TBRIF">OTCQB: TBRIF</a>) (FSE: JNX)A burgeoning name in the medical device industry, has achieved a significant breakthrough for its flagship product, the Venowave VW5. This circulation-enhancing device recently secured a crucial designation from the Centers for Medicare and Medicaid Services (CMS), positioning it for success within the expansive Medicare and Medicaid frameworks.The Venowave VW5 has been awarded a permanent Healthcare Common Procedure Coding System (HCPCS) code, a pivotal development that could propel Therma Bright into the forefront of the deep vein thrombosis (DVT) treatment market. Industry estimates project this market to grow to $1.5 billion by 2032, offering substantial growth prospects for Therma Bright, which currently holds a modest market cap of USD $21 million.Introducing Therma Bright: Innovating Blood Clot Prevention, and BeyondTherma Bright, Inc., the innovative force behind the Venowave VW5, specializes in cutting-edge diagnostic and medical device technologies. While the company boasts a diverse portfolio, the Venowave VW5 is currently generating the most investor enthusiasm.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_14_31_PM_5254def16f.png" alt="Screenshot 2024-09-10 at 5.14.31 PM.png">The Venowave VW5 is a device designed to be worn on the calf, where it generates wave-like motions to massage the leg and promote blood circulation. This function is critical in pushing blood back to the heart, helping to prevent blood clotting, particularly in cases of DVT—a condition that affects approximately 900,000 Americans annually, according to the CDC. Unlike traditional compression socks, which can cause discomfort and skin issues, the VW5 offers a more comfortable and effective alternative for DVT patients.Venowave VW5 Achieves Key Medicare &amp; Medicaid DesignationThe Venowave VW5 is the first device of its kind to be classified as Durable Medical Equipment (DME) with a new HCPCS Level II code. This designation enhances the device's credibility as a treatment option and streamlines billing and reimbursement processes through Medicare and Medicaid. This is expected to increase its appeal among patients seeking treatment for DVT.Medicare and Medicaid reimbursement is crucial for a company like Therma Bright because it opens the door to a vast and stable market of insured patients, ensuring consistent demand for their products. Securing reimbursement from these programs not only validates the effectiveness and necessity of their devices but also simplifies the purchasing process for patients and healthcare providers. For investors, this is a significant milestone as it enhances the company’s revenue potential and reduces financial risk, making Therma Bright a more attractive and reliable investment opportunity.As per the recent announcement, patients will have the option to purchase a pair of Venowave devices outright with a capped reimbursement of $1,199. Alternatively, they can opt for a rental plan, with monthly reimbursement capped at $78.05, totaling $819.55 over 13 months. Ownership of the device will transfer to the patient after the 13th rental payment.Strategic Distribution Partnership SecuredShortly after receiving its new designation, Therma Bright announced a partnership with a major distributor to launch an initial sales program. This initiative aims to assess Medicare and Medicaid reimbursement timelines and billing procedures. If successful, the distributor has agreed to purchase the remaining Venowave VW5 inventory, valued at $2.38 million.While the distributor's identity has not been disclosed, it is expected that further details will emerge as the program progresses. This partnership marks a crucial step towards establishing the VW5 as a preferred DVT treatment, particularly for patients covered by Medicare and Medicaid. Therma Bright's CEO, Rob Fia, anticipates a "significant increase" in monthly orders as a result.Beyond DVT: Expanding the Venowave VW5's ApplicationsWhile the Venowave VW5 is already gaining attention for its role in DVT treatment, its potential applications extend far beyond. The device is capable of addressing a wide range of conditions, significantly broadening Therma Bright's total addressable market.In addition to DVT, the VW5 can be used for:- Managing symptoms of post-thrombotic syndrome (PTS)- Preventing primary thrombosis- Treating lymphedema- Reducing post-operative pain and swelling- Alleviating leg swelling caused by vascular insufficiency- Treating varicose veins- Managing chronic venous insufficiency- Enhancing blood circulation- Addressing intermittent claudication&nbsp;All of these ailments represent blue sky for Therma Bright as each one of these very common medical issues, as they potentially become approved, would unlock a whole new category of customer for the company.&nbsp;Therma Bright's Diverse, Late-Stage Product Pipeline&nbsp;Therma Bright's diverse product portfolio is a key driver of its investor appeal, with its investment in Inretio at the forefront.&nbsp;Inretio is revolutionizing ischemic stroke treatment with its Preva® clot-retrieval device, which has recently completed its<a href="https://finance.yahoo.com/news/therma-bright-major-milestone-portfolio-100000110.html"> third successful human trial</a>. This groundbreaking technology represents a significant leap in thrombectomy procedures, offering unmatched precision in restoring blood flow for stroke patients, even when traditional treatments like tPA fail.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_28_PM_5b99c7f619.png" alt="Screenshot 2024-09-10 at 5.15.28 PM.png">The Preva® device's patented protective basket design reduces the risk of embolization and minimizes the need for repeated maneuvers, positioning it as a potential game-changer in the global market for advanced clot removal solutions. As Inretio progresses towards FDA 510K designation, the success of the Preva® device underscores the strategic value of Therma Bright's investment in cutting-edge medical technologies.With the global coronary stents market expected to reach $4.8 billion by 2029, the continued development of this device could greatly enhance Therma Bright's portfolio.The $16 Billion COPD MarketTherma Bright is making significant strides with its investment in InStatin, a company developing innovative inhaled statin therapies for respiratory diseases like asthma and Chronic Obstructive Pulmonary Disease (COPD). Unlike traditional statin therapies that are administered orally, InStatin’s novel delivery system targets the airways and lungs directly, potentially offering a more effective treatment at lower dosages. This cutting-edge approach could revolutionize the management of these respiratory conditions, which collectively affect over 600 million people globally.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_34_PM_afe9034042.png" alt="Screenshot 2024-09-10 at 5.15.34 PM.png">The global market for asthma and COPD treatments is substantial, with an estimated value exceeding $16 billion annually. This presents a significant growth opportunity for Therma Bright as InStatin progresses through pre-clinical stages. The unique benefits of inhaled statins—such as reduced tissue thinning and longer-lasting therapeutic effects compared to steroids—position this technology as a promising alternative in a market that has seen little innovation over the past 50 years.With a 17% equity stake in InStatin and a 60% stake in Invixa, Therma Bright is well-positioned to capitalize on the success of these therapies.Turn Your Head and CoughTherma Bright has also played a pivotal role in developing the Digital Cough Test in collaboration with AI4LYF. This innovative app uses artificial intelligence to monitor various respiratory diseases through cough analysis, further diversifying Therma Bright’s product offerings.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_39_PM_68fe2a4028.png" alt="Screenshot 2024-09-10 at 5.15.39 PM.png">Bringing it all TogetherTherma Bright's strategic focus on both medical devices and drug therapies places the company in a unique position within the healthcare sector. The company’s flagship products—ranging from the Venowave VW5 for DVT prevention to the Preva® clot-retrieval device and inhaled statin therapies—target significant, multi-billion-dollar markets. Combined, the market opportunities across these indications surpass $22 billion globally, highlighting the substantial revenue potential for Therma Bright which pales in comparison to their tiny market value of just USD $21 Million.What sets Therma Bright apart is its emphasis on medical devices, which typically face shorter, less expensive, and less risky development timelines compared to pharmaceutical drugs. The company's advancements with the Venowave VW5 and Preva® device, both of which are already far along in the regulatory process, partially de-risk their pipeline. This progress contrasts with the longer, more expensive, and more uncertain path often associated with drug development.&nbsp;By focusing on innovative medical devices that address large and unmet medical needs, Therma Bright is poised to potentially capture significant market share, offering a compelling growth story for investors as it continues to push the boundaries of healthcare innovation.

<h1>Tiny Healthcare Stock With $35 Million Market Cap Becomes Major Player Overnight in Rapidly Growing $1 Billion Market</h1><h2>Therma Bright (THRM) secures permanent Medicare and Medicaid reimbursement codes for Venowave VW5, making it the only product with reimbursement codes in deep vein thrombosis (DVT) market, expected to grow in value to US $1.55 billion by 2032.</h2>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/therma-bright">Therma Bright (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX)</a>, a leader in proprietary diagnostic and medical device technology, is making significant strides in addressing critical health challenges with its innovative solutions. The company’s&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.newsfilecorp.com/release/220400/Therma-Brights-Venowave-VW5-Secures-Permanent-HCPCS-Code-E0683-from-U.S.-DHHSs-Centers-for-Medicare-Medicaid-Services?k=therma%20bright">latest achievement</a>, the permanent Healthcare Common Procedure Coding System (HCPCS) code E0683 for its Venowave VW5 device, marks a crucial milestone in enhancing patient care and expanding market reach.<h3>Venowave VW5: A Revolutionary Approach to Circulatory Health</h3>The&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thermabright.com/venowave/">Venowave VW5</a> is a first-of-its-kind piece of Durable Medical Equipment designed to treat and prevent deep vein thrombosis (DVT) and other circulatory issues by utilizing a series of compact, battery-operated peristaltic pumps that generate a wave-form motion.Worn below the knee and strapped firmly to the calf, the Venowave device provides compression to the calf and creates an increased upward volumetric displacement of venous and lymph fluid, resulting in improved vascular and lymphatic flow in the lower limbs.The device, now recognized by the U.S. Department of Health &amp; Human Services’ Centers for Medicare and Medicaid Services (CMS) with its own HCPCS code, offers patients a much-needed alternative to traditional treatments like compression socks. Unlike compression socks, which can cause discomfort and skin issues, the Venowave VW5 uses its wave-form motion to gently massage the calf, improving blood circulation without the associated drawbacks.Rob Fia, CEO of Therma Bright, commented on the milestone announcement, stating:<blockquote>“We’re pleased that the Centers for Medicare and Medicaid has approved our permanent code request, as well as the reimbursement pricing and the new HCPCS Level II designation for our Venowave VW5 device. As shared in several of our recent press announcements, the CDC estimates that over 900,000 U.S. citizens suffer from deep vein thrombosis (DVT) and MarketDigit’s research projected this disease will ‘reach USD 1.5 Billion by 2032’ on a global market value perspective. And DVT is only one medical condition area out of ten circulatory issues that the permanent code will cover, which is very exciting.”</blockquote>The reimbursable codes are not only a great opportunity for Therma Bright but also for the company’s customers, reseller partners and shareholders.The Medicare and Medicaid codes for the Venowave VW5 cover the following ten indications:– Prevention of deep vein thrombosis (DVT) – Management of the symptoms of post-thrombotic syndrome (PTS) – Prevention of primary thrombosis – Treatment of lymphedema – Diminishing post-operative pain and swelling – Treatment of leg swelling due to vascular insufficiency – Treatment of varicose veins – Treatment of chronic venous insufficiency – Enhancing blood circulation – Treatment of intermittent claudicationPer this morning’s Therma Bright&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.newsfilecorp.com/release/220400/Therma-Brights-Venowave-VW5-Secures-Permanent-HCPCS-Code-E0683-from-U.S.-DHHSs-Centers-for-Medicare-Medicaid-Services?k=therma%20bright">press release</a>, the Venowave VW5 will have a complete patient buyout option for a pair of Venowave devices with a capped reimbursement of $1,199.The Venowave VW5 can also be rented with a capped rental fee reimbursement of $78.05 per month. The total capped rental reimbursement payment for 13 months of continuous use is $819.55, and following the 13th rental payment, the patient will become the owner of the Venowave VW5.The device’s impact is underscored by the growing need for effective DVT treatments. The global market for DVT prevention is&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/en/news-release/2024/01/29/2819535/28124/en/Deep-Vein-Thrombosis-Market-Projected-to-Ascend-to-1-26-billion-by-2028-A-Fresh-Global-Market-Report-Unveiled.html">projected to grow</a> steadily at a CAGR of 4.1% and reach US $1.26 billion by 2028 and US $1.55 billion by 2032, driven by an aging population and the increasing prevalence of lifestyle diseases like obesity. With over 900,000 Americans affected by DVT annually, the Venowave VW5 is poised to play a critical role in managing and preventing this life-threatening condition.Highlighting the significance of the development, Fia added:<blockquote>“This innovative device for addressing DVT and these other blood circulation issues is the first-of-its-kind to receive the permanent HCPCS Level II code, and we look to provide an initial sales update on our solution in the coming week. One key competitive product in the marketplace is the compression sock, which applies controlled and constant pressure on the leg to improve blood flow in the veins. Unfortunately, users of the compression socks can experience a variety of challenges, including difficulty in putting the sock on, discomfort from constant pressure, minor bruising, skin ulcers, dry skin, redness, and itching. In contrast, the Venowave VW5 simply straps on and massages the leg, applying appropriate pressure in a comfortable and soothing manner to circulate blood through the veins.”</blockquote><h3>Expanding the Portfolio: AI-Powered Solutions and Strategic Investments</h3><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thermabright.com/">Therma Bright</a>‘s commitment to innovation extends beyond the Venowave VW5. The company is also at the forefront of integrating artificial intelligence (AI) into healthcare, as demonstrated by its Digital Cough Technology (DCT). Developed in partnership with&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thermabright.com/ai4lyf/">AI4LYF</a>, this AI-powered platform is currently&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.newsfilecorp.com/release/220173/Therma-Brights-AIPowered-Digital-Cough-Technology-Being-Considered-as-Partner-Technology-in-New-Chronic-Cough-Drug-Clinical-Trial">under consideration</a> for a U.S. clinical trial involving a new chronic cough drug. The DCT platform enables healthcare providers and epidemiologists to make more accurate and informed decisions by analyzing cough sounds, thereby improving the diagnosis and management of respiratory conditions.Fia explained:<blockquote>“Our DCT solution and data collection platform is ideally positioned for clinical studies like this one. It allows health practitioners to quickly address a patient’s respiratory issues, ultimately leading to better health outcomes.”</blockquote>Therma Bright’s strategic investments further solidify its position in the medical device industry. The company’s portfolio includes a stake in Inretio, which is revolutionizing ischemic stroke treatment with its innovative clot-retrieving device, PREVATM. This technology has shown promising results in early trials, achieving an 80% success rate compared to the 50% effectiveness of existing devices. Additionally, Therma Bright is developing inhaled statin therapies for asthma and COPD, offering a new approach to treating these widespread respiratory conditions.<h3>The Road Ahead: A Focus on Patient-Centered Innovation</h3>Therma Bright’s focus on patient-centred innovation is evident in its approach to product development and market expansion. The company’s Venowave VW5 not only provides a new standard in DVT treatment but also sets the stage for further advancements in circulatory and respiratory health.As the healthcare landscape continues to evolve, Therma Bright is well-positioned to lead the way with its cutting-edge technologies. With the Venowave VW5 already making waves in the market and its AI-powered DCT platform on the brink of clinical integration, the company is poised to make a lasting impact on the health and well-being of millions.<h3>Therma Bright (TSXV: THRM) Stock Price Action</h3>Shares of Therma Bright stock are in the midst of an epic breakout, with THRM stock up as much as&nbsp;350% since July 31, 2024, and as much as&nbsp;800% since May 31, 2024.Therma Bright stock last traded at $0.085. YTD, THRM stock is up&nbsp;183.33%.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_20_at_7_52_22_PM_ae153f1a0d.png" alt="Screenshot 2024-08-20 at 7.52.22 PM.png" width="1436" height="864">Therma Bright, (TSXV: THRM), six-month interactive stock chart. (Source: Barchart)<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.barchart.com/stocks/quotes/THRM.VN/interactive-chart">View Therma Bright Stock Chart on Barchart</a>Read Next:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/biotech/tempest-therapeutics-tpst-stock-jumps-83-on-fda-phase-3-trial-news/">Tempest Therapeutics (TPST) Stock Jumps 83% on FDA Phase 3 Trial News</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at&nbsp;Invest@WealthyVC.comTherma Bright Inc. (CSE: PAID) is a paid client of Wealthy VC. This report/release/profile is a commercial advertisement and is for general information purposes only.&nbsp;&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

Tiny Healthcare Stock With $35 Million Market Cap Becomes Major Player Overnight in Rapidly Growing $1 Billion Market

Therma Bright secures Medicare codes for its Venowave VW5, boosting its market presence in the $1.5B DVT market and driving an 800% stock surge since May 2024.

Therma Bright Gains Medicare Code for Venowave, Stock Soars

Equity

Therma Bright (TSXV: THRM) secures permanent Medicare and Medicaid reimbursement codes for its Venowave VW5 device, making it the only DVT treatment with such codes. This innovation has driven significant stock gains, with shares rising over 800% since May 2024.

Therma Bright, Inc. engages in developing and marketing skin care medical device products. Its products include Therapik, which is used to relieve the pain, itch and inflammation of stings and bites from different species of insects and InterceptCS, which is a device to prevent cold sore outbreaks. The company was founded in 2001 and is headquartered in Toronto, Canada.

TBRIF
Therma Bright Inc

Feed

News

Sentiment

Fundamentals

Info

Latest TBRIF News

TBRIF Therma Bright Inc